Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

Stopped FDA reviewers asked for Phase 1 study in Oncology subjects, not in healthy volunteers.

Conditions

• Advanced Solid Tumor

Interventions

• DRUG: ONC-841
• OTHER: Placebo

Sponsor

OncoC4, Inc.